Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
This page provides a historical news archive for Arena Pharmaceuticals, Inc. (ARNA), a clinical-stage biopharmaceutical company that focused on developing investigational therapies for immuno-inflammatory and cardiovascular diseases. The news flow around ARNA captured key milestones in its clinical programs, corporate developments, and the definitive agreement under which Pfizer agreed to acquire Arena in an all-cash transaction.
Readers can review company-issued press releases covering progress in Arena’s gastroenterology, dermatology, and cardiology pipelines. These include updates on the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials of etrasimod in ulcerative colitis, the Phase 2/3 CULTIVATE program in Crohn’s disease, and Phase 2 studies of etrasimod in atopic dermatitis and alopecia areata. Additional news items describe Phase 2 development of cardiovascular assets temanogrel and APD418, as well as collaborations and option agreements related to other investigational compounds.
The archive also contains quarterly and annual financial result announcements, which detail Arena’s research and development spending, selling, general and administrative expenses, and net losses as it advanced its clinical-stage portfolio. Corporate governance and compensation-related releases, such as inducement grants under Nasdaq Listing Rule 5635(c)(4), provide further insight into Arena’s growth and hiring during its development phase.
Because Arena entered into an acquisition agreement with Pfizer, these news items primarily serve as historical context for ARNA rather than current standalone company updates. Investors, researchers, and students of the biopharmaceutical sector can use this record to trace how Arena communicated the evolution of its pipeline, its financial profile as a clinical-stage company, and the strategic rationale presented when Pfizer announced its plan to acquire Arena.
Arena Pharmaceuticals (Nasdaq: ARNA) will announce its first quarter 2021 financial results and corporate update on May 5, 2021, after U.S. market close. The company will hold a conference call at 4:30 PM ET for investors, providing a platform for questions and discussion. Participants are encouraged to join 20 minutes early for registration. Arena Pharmaceuticals is committed to delivering essential medicines and has emphasized its focus on executing disruptive ideas in the healthcare sector.
Arena Pharmaceuticals (Nasdaq: ARNA) presented additional data from its ADVISE Phase 2b trial for etrasimod, an investigational treatment for moderate-to-severe atopic dermatitis, at the American Academy of Dermatology VMX Experience. The 2 mg dose of etrasimod showed statistically significant improvements in both clinician and patient-reported outcomes. Key results included a 29.8% reduction in the vIGA score and significant enhancements in peak pruritis and overall quality of life measures. Arena plans to advance etrasimod into a Phase 3 program, highlighting its potential as a novel treatment option.
Summary not available.
Arena Pharmaceuticals (Nasdaq: ARNA) will present data from its Phase 2b ADVISE trial on etrasimod, an oral S1P receptor modulator for moderate-to-severe atopic dermatitis, at the American Academy of Dermatology Virtual Meeting from April 23-25, 2021. The study aims to demonstrate improvements in patient and clinician-reported outcomes. Etrasimod, still investigational and not yet approved, targets multiple immune-mediated inflammatory diseases including atopic dermatitis, ulcerative colitis, and Crohn's disease.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on April 15, 2021, the grant of inducement stock options and restricted stock units (RSUs) to 17 new employees. The total includes 50,785 stock options and 20,490 RSUs, with a grant date and vesting commencement on April 15, 2021. The stock options have a seven-year term with an exercise price of $67.99 per share and vesting over four years. The RSUs also vest over four years, with a similar structure. These grants comply with Nasdaq Listing Rule 5635(c)(4).
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options, performance restricted stock units (PRSUs), and restricted stock units (RSUs) to new employees as per Nasdaq Listing Rule 5635(c)(4). The options include 40,000 shares to Mike Paolucci, 12,900 shares to four new employees, and 5,595 RSUs. The stock options have a seven-year term with an exercise price of $77.58 and vesting over four years. PRSUs will vest based on the stock price reaching specific thresholds by February 2024. This initiative aims to attract talent and align employee interests with company performance.
Arena Pharmaceuticals (Nasdaq: ARNA) announced topline results from the Phase 2b CAPTIVATE trial of olorinab, a cannabinoid receptor 2 (CB2) full agonist, in patients with abdominal pain from Irritable Bowel Syndrome (IBS). The study included 273 participants and showed that while olorinab was well tolerated, it did not fulfill its primary efficacy endpoint. However, a subgroup with moderate to severe pain (50% of participants) experienced a statistically significant reduction in pain scores with the 50 mg dose. No serious adverse events were reported, suggesting a favorable safety profile.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported its fourth quarter and full year 2020 financial results. The company noted the completion of enrollment for the ELEVATE UC 52 trial and initiated the Phase 2b VOYAGE trial for etrasimod. Despite advancements, revenues for Q4 were zero compared to $3.0 million last year, while net loss increased to $122.2 million. R&D expenses surged to $100.4 million, reflecting ongoing clinical studies. The company maintains a strong cash position of approximately $1.1 billion, supporting its diverse pipeline.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on February 15, 2021, the granting of inducement stock options for 33,885 shares and 8,475 restricted stock units (RSUs) to eleven new employees. The stock options have a seven-year term, an exercise price of $83.95 per share, and vest over four years. RSUs also vest over four years, with a similar structure for timing and conditions. These grants are made in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to encourage new hires to join Arena’s team.
Arena Pharmaceuticals (Nasdaq: ARNA) will announce its Q4 and full-year 2020 financial results on February 23, 2021, after U.S. market close. A conference call and live webcast for investors will take place on the same day at 4:30 PM ET. Interested parties can join by dialing (877) 643-7155 for the U.S. or (914) 495-8552 internationally, using conference ID 1778476. A replay will be available for 30 days. The company is committed to delivering essential medicines, focusing on stakeholder needs and innovative solutions.